Advertisement

Click here for more guidelines.
2012 ACCF/ AATS/ SCAI/ STS Expert Consensus Document on Transcatheter Aortic Valve Replacement
ACCF/ SCAI/ STS/ AATS/ AHA/ ASNC/ HFSA/ SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update
2012 ACCF/ AHA/ ACR/ SCAI/ SIR/ STS/ SVM/ SVN Key Data Elements and Definitions for Peripheral Atherosclerotic Vascular Disease

 
About JACC CME
Policy on Privacy and Confidentiality
Disclosures
Important Information
 

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME
 
 

Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions
 
 

About the Journal
Editorial Board & Staff
 
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2005; 46:529-535, doi:10.1016/j.jacc.2005.04.050 (Published online 14 July 2005).
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Only Appendix
Right arrow All Versions of this Article:
j.jacc.2005.04.050v1
46/3/529    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (122)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galié, N.
Right arrow Articles by Rubin, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galié, N.
Right arrow Articles by Rubin, L. J.

CLINICAL RESEARCH: PULMONARY HYPERTENSION

Ambrisentan Therapy for Pulmonary Arterial Hypertension

Nazzareno Galié, MD*,*, David Badesch, MD{dagger}, Ronald Oudiz, MD{ddagger}, Gérald Simonneau, MD§, Michael D. McGoon, MD||, Anne M. Keogh, MD, Adaani E. Frost, MD#, Diane Zwicke, MD**, Robert Naeije, MD{dagger}{dagger}, Shelley Shapiro, MD, PhD{ddagger}{ddagger}, Horst Olschewski, MD§§ and Lewis J. Rubin, MD||||

* University of Bologna, Bologna, Italy
{dagger} University of Colorado Health Science Center, Denver, Colorado
{ddagger} Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California
§ Hôpital Antoine Béclère, Clamart, France
|| Mayo Clinic College of Medicine, Rochester, Minnesota
Saint Vincent’s Hospital, Darlinghurst, Australia
# Baylor College of Medicine and the Methodist Hospital, Houston, Texas
** St. Luke’s/Aurora Sinai Medical Centers, University of Wisconsin Medical School-Milwaukee Clinical Campus, Milwaukee, Wisconsin
{dagger}{dagger} Erasmus University, Brussels, Belgium
{ddagger}{ddagger} University of Southern California, Keck School of Medicine, Los Angeles, California
§§ University Giessen Lung Center, Giessen, Germany
|||| University of California-San Diego, San Diego, California

Manuscript received December 3, 2004; revised manuscript received March 24, 2005, accepted April 14, 2005.

* Reprint requests and correspondence: Prof. Nazzareno Galié, Institute of Cardiology, University of Bologna, Via Massarenti 9, Bologna, Italy 40138 (Email: n.galie{at}bo.nettuno.it).

OBJECTIVES: The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH).

BACKGROUND: Pulmonary arterial hypertension is a life-threatening and progressive disease with limited treatment options. Endothelin is a vasoconstrictor and smooth muscle cell mitogen that plays a critical role in the pathogenesis and progression of PAH.

METHODS: In this double-blind, dose-ranging study, 64 patients with idiopathic PAH or PAH associated with collagen vascular disease, anorexigen use, or human immunodeficiency virus infection were randomized to receive 1, 2.5, 5, or 10 mg of ambrisentan once daily for 12 weeks followed by 12 weeks of open-label ambrisentan. The primary end point was an improvement from baseline in 6-min walk distance (6MWD); secondary end points included Borg dyspnea index, World Health Organization (WHO) functional class, a subject global assessment, and cardiopulmonary hemodynamics.

RESULTS: At 12 weeks, ambrisentan increased 6MWD (+36.1 m, p < 0.0001) with similar and statistically significant increases for each dose group (range, +33.9 to +38.1 m). Improvements were also observed in Borg dyspnea index, WHO functional class, subject global assessment, mean pulmonary arterial pressure (–5.2 mm Hg, p < 0.0001), and cardiac index (+0.33 l/min/m2, p < 0.0008). Adverse events were mild and unrelated to dose, including the incidence of elevated serum aminotransferase concentrations >3 times the upper limit of normal (3.1%).

CONCLUSIONS: Ambrisentan appears to improve exercise capacity, symptoms, and hemodynamics in patients with PAH. The incidence and severity of liver enzyme abnormalities appear to be low.

Abbreviations and Acronyms
  6MWD = 6-min walk distance
  ERA = endothelin receptor antagonist
  ET = endothelin
  IPAH = idiopathic pulmonary arterial hypertension
  mPAP = mean pulmonary arterial pressure
  PAH = pulmonary arterial hypertension
  PCWP = pulmonary capillary wedge pressure
  PVR = pulmonary vascular resistance
  WHO = World Health Organization




This article has been cited by other articles:


Home page
 CirculationHome page
R. J. Barst, D. D. Ivy, G. Gaitan, A. Szatmari, A. Rudzinski, A. E. Garcia, B. K. S. Sastry, T. Pulido, G. R. Layton, M. Serdarevic-Pehar, et al.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension
Circulation, January 17, 2012; 125(2): 324 - 334.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Condliffe
Living with pulmonary hypertension: quality not just quantity
Eur. Respir. J., September 1, 2011; 38(3): 512 - 513.
[Full Text] [PDF]

Home page
 Crit Care NurseHome page
C. Weber, M. Silver, D. Cromer, S. Kaminski, T. Wirick, and J. Vallejo
Under Pressure: Pulmonary Arterial Hypertension . . . A Mother's Struggle
Crit. Care Nurse, August 1, 2011; 31(4): 87 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. J. Barst, S. I. Ertel, M. Beghetti, and D. D. Ivy
Pulmonary arterial hypertension: a comparison between children and adults
Eur. Respir. J., March 1, 2011; 37(3): 665 - 677.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir RevHome page
R. L. Cordina and D. S. Celermajer
Therapeutic approaches in adults with congenital heart disease-associated pulmonary arterial hypertension
Eur. Respir. Rev., December 1, 2010; 19(118): 300 - 307.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir RevHome page
R. M. F. Berger and D. Bonnet
Treatment options for paediatric pulmonary arterial hypertension
Eur. Respir. Rev., December 1, 2010; 19(118): 321 - 330.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. B. Badesch, G. E. Raskob, C. G. Elliott, A. M. Krichman, H. W. Farber, A. E. Frost, R. J. Barst, R. L. Benza, T. G. Liou, M. Turner, et al.
Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry
Chest, February 1, 2010; 137(2): 376 - 387.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir RevHome page
J-L Vachiery and A. Davenport
The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses
Eur. Respir. Rev., December 1, 2009; 18(114): 260 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
The Task Force for the Diagnosis and Treatment of, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension
Eur. Respir. J., December 1, 2009; 34(6): 1219 - 1263.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. B. Badesch, H. C. Champion, M. A. Gomez Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R. J. Oudiz, et al.
Diagnosis and Assessment of Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol., June 30, 2009; 54(1_Suppl_S): S55 - S66.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. J. Barst, J. S. R. Gibbs, H. A. Ghofrani, M. M. Hoeper, V. V. McLaughlin, L. J. Rubin, O. Sitbon, V. F. Tapson, and N. Galie
Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol., June 30, 2009; 54(1_Suppl_S): S78 - S84.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
V. V. McLaughlin, D. B. Badesch, M. Delcroix, T. R. Fleming, S. P. Gaine, N. Galie, J. S. R. Gibbs, N. H. Kim, R. J. Oudiz, A. Peacock, et al.
End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol., June 30, 2009; 54(1_Suppl_S): S97 - S107.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Galie, B. H. Brundage, H. A. Ghofrani, R. J. Oudiz, G. Simonneau, Z. Safdar, S. Shapiro, R. J. White, M. Chan, A. Beardsworth, et al.
Tadalafil Therapy for Pulmonary Arterial Hypertension
Circulation, June 9, 2009; 119(22): 2894 - 2903.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619.
[Full Text] [PDF]

Home page
 CirculationHome page
Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association
Circulation, April 28, 2009; 119(16): 2250 - 2294.
[Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
K. A. Pesaturo, P. N. Johnson, and E. Z. Ramsey
Pediatric Pulmonary Hypertension: A Pharmacotherapeutic Review
Journal of Pharmacy Practice, April 1, 2009; 22(2): 166 - 178.
[Abstract] [PDF]

Home page
 ChestHome page
M. D. McGoon, A. E. Frost, R. J. Oudiz, D. B. Badesch, N. Galie, H. Olschewski, V. V. McLaughlin, M. J. Gerber, C. Dufton, D. J. Despain, et al.
Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
Chest, January 1, 2009; 135(1): 122 - 129.
[Abstract] [Full Text] [PDF]

Home page
 ESC Textbook of Cardiovascular MedicineHome page
N. Galie and A. Manes
CHAPTER 24 Pulmonary Hypertension
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Spence, A. Mandagere, C. Dufton, and J. Venitz
Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy Volunteers
J. Clin. Pharmacol., December 1, 2008; 48(12): 1451 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. L Hrometz and K. M Shields
Role of Ambrisentan in the Management of Pulmonary Hypertension
Ann. Pharmacother., November 1, 2008; 42(11): 1653 - 1659.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
H. A. Ghofrani, M. W. Wilkins, and S. Rich
Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension
Circulation, September 9, 2008; 118(11): 1195 - 1201.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Eur. Heart J., August 2, 2008; 29(16): 1936 - 1948.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert
Review: Therapeutic advances in pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265.
[Abstract] [PDF]

Home page
 Proc Am Thorac SocHome page
M. Gomberg-Maitland
Traditional and Alternative Designs for Pulmonary Arterial Hypertension Trials
Proceedings of the ATS, July 15, 2008; 5(5): 610 - 616.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
H. Chen, D. B. Taichman, and R. L. Doyle
Health-related Quality of Life and Patient-reported Outcomes in Pulmonary Arterial Hypertension
Proceedings of the ATS, July 15, 2008; 5(5): 623 - 630.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Galie, H. Olschewski, R. J. Oudiz, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al.
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Circulation, June 10, 2008; 117(23): 3010 - 3019.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Dupuis and M. M. Hoeper
Endothelin receptor antagonists in pulmonary arterial hypertension
Eur. Respir. J., February 1, 2008; 31(2): 407 - 415.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. Petersen, M. Deja, R. Bartholdy, B. Donaubauer, S. Laudi, R. C. E. Francis, W. Boemke, U. Kaisers, and T. Busch
Inhalation of the ETA receptor antagonist LU-135252 selectively attenuates hypoxic pulmonary vasoconstriction
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R601 - R605.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
T. Thenappan, S. J. Shah, S. Rich, and M. Gomberg-Maitland
A USA-based registry for pulmonary arterial hypertension: 1982 2006
Eur. Respir. J., December 1, 2007; 30(6): 1103 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
S. Takaoka, J. L. Faul, and R. Doyle
Current Therapies for Pulmonary Arterial Hypertension
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 137 - 148.
[Abstract] [PDF]

Home page
 ChestHome page
D. B. Badesch, S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. McLaughlin
Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines
Chest, June 1, 2007; 131(6): 1917 - 1928.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. M. Hoeper, S. H. Lee, R. Voswinckel, M. Palazzini, X. Jais, A. Marinelli, R. J. Barst, H. A. Ghofrani, Z.-C. Jing, C. Opitz, et al.
Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2546 - 2552.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
O. Distler, F. Behrens, D. Huscher, I. Foeldvari, A. Zink, P. Nash, C. P. Denton, M. Humbert, M. Matucci-Cerinic, J. Seibold, et al.
Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis
Rheumatology, December 1, 2006; 45(12): 1455 - 1457.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. I. Said
Mediators and modulators of pulmonary arterial hypertension
Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
O. Distler and A. Pignone
Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment
Rheumatology, October 1, 2006; 45(suppl_4): iv22 - iv25.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. J. Rubin
Endothelin-1 and the Pulmonary Vascular Response to Altitude: A New Therapeutic Target?
Circulation, September 26, 2006; 114(13): 1350 - 1351.
[Full Text] [PDF]

Home page
 CirculationHome page
V. V. McLaughlin and M. D. McGoon
Pulmonary Arterial Hypertension
Circulation, September 26, 2006; 114(13): 1417 - 1431.
[Full Text] [PDF]

Home page
 J. Physiol.Home page
B. Houweling, D. Merkus, O. Sorop, F. Boomsma, and D. J. Duncker
Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction
J. Physiol., July 15, 2006; 574(2): 615 - 626.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan
Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug
Exp Biol Med, June 1, 2006; 231(6): 653 - 695.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. M. Hoeper and L. J. Rubin
Update in pulmonary hypertension 2005.
Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 499 - 505.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
L. J. Rubin
Pulmonary arterial hypertension.
Proceedings of the ATS, January 1, 2006; 3(1): 111 - 115.
[Abstract] [Full Text] [PDF]


 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement